Evidence map›Paper›PMID 23974215›Full record

ArticleInflammation research : official journal of the European Histamine Research Society ... [et al.]2013

Vimentin is a target of PKCβ phosphorylation in MCP-1-activated primary human monocytes.

Praveena S Thiagarajan, Ayse C Akbasli, Michael T Kinter, Belinda Willard, Martha K Cathcart

Open access · greenAbstract read
In one paragraph

Article in Inflammation research : official journal of the European Histamine Research Society ... [et al.], 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 2 countries.

Praveena S ThiagarajanDepartment of Cellular and Molecular Medicine, Lerner Research Institute, Cleveland Clinic Foundation, 9500 Euclid Ave., Cleveland, OH, 44195, USA.
Ayse C Akbasli
Michael T Kinter
Belinda Willard
Martha K Cathcart
Cleveland Clinic · USCleveland Clinic Lerner College of Medicine · USIstanbul University · TR

Funding

CTSA INFRASTRUCTURE FOR PEDIATRIC RESEARCHUL1RR024989 · NCRR · CASE WESTERN RESERVE UNIVERSITY · PI DAVIS, PAMELA B · 2007 to 2011
$53.7M
REGULATION OF MONOCYTE 15-LIPOXYGENASE EXPRESSIONP01HL087018 · NHLBI · CLEVELAND CLINIC LERNER COM-CWRU · PI MCINTYRE, THOMAS M · 2007 to 2011
$11.4M
MONOCYTE PATHOGENESIS--RESPIRATORY BURST OXIDASER01HL061971 · NHLBI · CLEVELAND CLINIC LERNER COM-CWRU · PI CATHCART, MARTHA K · 1999 to 2007
$2.1M
PHOSPHOLIPASE REGULATION OF MONOCYTE CHEMOTAXIS TO MCP-1R01HL074451 · NHLBI · CLEVELAND CLINIC LERNER COM-CWRU · PI CATHCART, MARTHA K · 2003 to 2006
$1.4M
MONOCYTE OXIDATION OF LIPOPROTEIN LIPIDSR01HL051068 · NHLBI · CLEVELAND CLINIC FOUNDATION · PI CATHCART, MARTHA K · 1995 to 2002
$778k
NCRR NIH HHS 1UL1RR024989NCRR NIH HHS UL1 RR024989NHLBI NIH HHS HL051068NHLBI NIH HHS HL087018NHLBI NIH HHS HL61971NHLBI NIH HHS P01 HL087018NHLBI NIH HHS R01 HL061971NHLBI NIH HHS R01 HL074451
6 · The paper itself

Abstract

OBJECTIVE AND

designWe designed a study to detect downstream phosphorylation targets of PKCβ in MCP-1-induced human monocytes.

methodsTwo-dimensional gel electrophoresis was performed for monocytes treated with MCP-1 in the presence or absence of PKCβ antisense oligodeoxyribonucleotides (AS-ODN) or a PKCβ inhibitor peptide, followed by phospho- and total protein staining. Proteins that stained less intensely with the phospho-stain, when normalized to the total protein stain, in the presence of PKCβ AS-ODN or the PKCβ inhibitor peptide, were sequenced.

resultsOf the proteins identified, vimentin was consistently identified using both experimental approaches. Upon (32)P-labeling and vimentin immunoprecipitation, increased phosphorylation of vimentin was observed in MCP-1 treated monocytes as compared to the untreated monocytes. Both PKCβ AS-ODN and the PKCβ inhibitor reduced MCP-1-induced vimentin phosphorylation. The IP of monocytes with anti-vimentin antibody and immunoblotting with a PKCβ antibody revealed that increased PKCβ becomes associated with vimentin upon MCP-1 activation. Upon MCP-1 treatment, monocytes were shown to secrete vimentin and secretion depended on PKCβ expression and activity.

conclusionsWe conclude that vimentin, a major intermediate filament protein, is a phosphorylation target of PKCβ in MCP-1-treated monocytes and that PKCβ phosphorylation is essential for vimentin secretion. Our recently published studies have implicated vimentin as a potent stimulator of the innate immune receptor Dectin-1 as reported by Thiagarajan et al. (Cardiovasc Res 99:494-504, 2013). Taken together our findings suggest that inhibition of PKCβ regulates vimentin secretion and, thereby, its interaction with Dectin-1 and downstream stimulation of superoxide anion production. Thus, PKCβ phosphorylation of vimentin likely plays an important role in propagating inflammatory responses.

Indexed as

Cells, CulturedChemokine CCL2HumansMonocytesPhosphorylationProtein Kinase C betaVimentinCCL2 protein, humanChemokine CCL2Protein Kinase C betaVimentin

Identifiers

PMID23974215
PMCPMC3831879
OpenAlexW2025458344

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.